Post-Cycle Therapy (PCT)

Overview

Post-Cycle Therapy (PCT) refers to a structured protocol designed to restore the hypothalamic-pituitary-gonadal (HPG) axis after it has been suppressed by exogenous androgen use (anabolic steroids, testosterone replacement, or SARMs). When exogenous androgens are introduced, the body's natural feedback loop reduces endogenous testosterone production — the hypothalamus decreases GnRH (gonadotropin-releasing hormone) output, the pituitary reduces LH (luteinizing hormone) and FSH (follicle-stimulating hormone) secretion, and the testes decrease testosterone synthesis.

Without PCT, recovery of the HPG axis can take months to years, during which individuals may experience low testosterone symptoms: fatigue, mood disturbances, loss of muscle mass, increased body fat, decreased libido, and potential long-term fertility impairment.

Peptide-based PCT protocols use compounds that stimulate different levels of the HPG axis to accelerate recovery. This approach differs from traditional PCT (which relied primarily on SERMs like Clomiphene and Tamoxifen) by targeting the signaling cascade at multiple points — from the hypothalamus (Kisspeptin), through the pituitary (Gonadorelin), to the gonadal level (Enclomiphene).

Compounds Involved

Compound	Target Level	Mechanism	Typical Dose	Route
Gonadorelin	Pituitary	GnRH analog — directly stimulates LH/FSH release	100–200 mcg 2–3x/day	SubQ
Kisspeptin-10	Hypothalamus	Stimulates endogenous GnRH release from hypothalamus	100–200 mcg 1–2x/day	SubQ
Enclomiphene	Hypothalamus/Pituitary	Selective estrogen receptor modulator — blocks negative feedback	12.5–25 mg/day	Oral

Gonadorelin

Gonadorelin is a synthetic analog of GnRH (gonadotropin-releasing hormone), the master signal that tells the pituitary to produce LH and FSH. By administering pulsatile GnRH, Gonadorelin helps "re-awaken" suppressed pituitary gonadotropes. The pulsatile nature of administration is important — continuous GnRH stimulation paradoxically suppresses the pituitary (this is the mechanism of GnRH agonist drugs used for prostate cancer), while pulsatile delivery mimics the body's natural rhythmic GnRH secretion.

Kisspeptin

Kisspeptin is a neuropeptide produced by neurons in the hypothalamus that sits upstream of GnRH signaling. Kisspeptin neurons are the primary regulators of GnRH pulse generation. By stimulating kisspeptin receptors (GPR54/KISS1R), exogenous kisspeptin activates the entire HPG cascade from its highest regulatory point. This makes Kisspeptin particularly valuable when the hypothalamus itself has been suppressed during long or heavy cycles.

Enclomiphene

Enclomiphene is the trans-isomer of Clomiphene citrate. Traditional Clomiphene (Clomid) contains both the trans (Enclomiphene) and cis (Zuclomiphene) isomers. Enclomiphene is the isomer responsible for the anti-estrogenic effects at the hypothalamus and pituitary — blocking estrogen-mediated negative feedback and thereby increasing GnRH, LH, and FSH output. Zuclomiphene, by contrast, has estrogenic activity and a long half-life, contributing to many of the side effects associated with traditional Clomid (mood disturbances, visual changes).

Isolated Enclomiphene provides the testosterone-stimulating benefits of Clomiphene without the estrogenic side effects of Zuclomiphene.

Protocol Structure

Phase 1: Activation (Weeks 1–2)

This phase begins immediately after the last dose of the suppressive compound (adjusted for the compound's half-life — long-ester compounds may require a washout period before PCT begins).

Gonadorelin:

• Dose: 100–200 mcg per injection
• Frequency: 2–3 times daily (pulsatile dosing is critical — spaced 4–8 hours apart)
• Route: Subcutaneous injection

Kisspeptin-10:

• Dose: 100–200 mcg per injection
• Frequency: Once or twice daily
• Route: Subcutaneous injection

Enclomiphene:

• Dose: 25 mg per day
• Route: Oral

Phase 2: Consolidation (Weeks 3–6)

The HPG axis has begun to respond. Dosing is adjusted to support continued recovery without overstimulation.

Gonadorelin:

• Dose: 100 mcg per injection
• Frequency: Twice daily

Kisspeptin-10:

• Dose: 100 mcg per injection
• Frequency: Once daily

Enclomiphene:

• Dose: 12.5–25 mg per day

Phase 3: Taper and Discontinuation (Weeks 7–8)

Gradual tapering allows the axis to sustain function independently.

Gonadorelin:

• Reduce to once daily for 1 week, then discontinue

Kisspeptin-10:

• Discontinue at the start of this phase

Enclomiphene:

• Reduce to 12.5 mg/day for 1 week, then 12.5 mg every other day for 1 week, then discontinue

Protocol Summary Table

Phase	Weeks	Gonadorelin	Kisspeptin-10	Enclomiphene
Activation	1–2	100–200 mcg 2–3x/day	100–200 mcg 1–2x/day	25 mg/day
Consolidation	3–6	100 mcg 2x/day	100 mcg 1x/day	12.5–25 mg/day
Taper	7–8	100 mcg 1x/day, then stop	Stop	12.5 mg/day, then EOD, then stop

Timing PCT Start

When to begin PCT depends on the half-life of the suppressive compound used:

Compound Type	Approximate Clearance	Start PCT
Short-ester testosterone (propionate)	3–4 days	3–4 days after last injection
Medium-ester (enanthate, cypionate)	2–3 weeks	2 weeks after last injection
Long-ester (undecanoate)	4–5 weeks	4 weeks after last injection
SARMs (most)	1–3 days	1–3 days after last dose
Oral anabolics	1–2 days	Day after last dose

Starting PCT while the suppressive compound is still active wastes the PCT compounds — the exogenous androgens continue to suppress the axis despite PCT intervention.

Blood Work and Monitoring

Laboratory testing is essential for both guiding PCT timing and confirming recovery. See blood work monitoring for details:

Pre-PCT Blood Work (drawn 1–2 weeks before starting PCT)

• Total testosterone
• Free testosterone
• LH and FSH
• Estradiol (E2)
• SHBG (sex hormone-binding globulin)
• Complete blood count

Post-PCT Blood Work (drawn 4–6 weeks after completing PCT)

• Same panel as above
• Compare to pre-cycle baseline (if available)

Recovery indicators:

• LH and FSH returning to mid-normal or above
• Total testosterone above 400 ng/dL (ideally returning to pre-cycle baseline)
• Estradiol within normal reference range

If post-PCT blood work shows persistently suppressed values, a second PCT course or medical evaluation may be warranted.

Important Considerations

• Severity of suppression varies: A short, mild SARM cycle may require only 4 weeks of PCT with Enclomiphene alone. A prolonged, heavy steroid cycle with multiple compounds may need the full 8-week multi-compound protocol. Scale the PCT to the degree of suppression.
• Pulsatile dosing of Gonadorelin is critical: Continuous GnRH stimulation causes pituitary desensitization (downregulation). Doses must be spaced throughout the day to mimic natural pulsatile release.
• Fertility considerations: If fertility preservation is a concern, HCG (human chorionic gonadotropin) may be used during the suppressive cycle to maintain testicular function, making subsequent PCT more effective. This is a medical decision requiring physician guidance.
• Age matters: Younger individuals generally recover HPG axis function more readily. Older individuals (40+) who have been on long-term suppression may have more difficulty achieving full recovery.
• No shortcuts: Skipping PCT after a suppressive cycle is a common but risky decision. Even if symptoms feel manageable initially, prolonged hypogonadism has metabolic, cardiovascular, and psychological consequences.
• Medical supervision recommended: PCT involves hormonal manipulation and should ideally be conducted under the guidance of a physician experienced in hormonal management.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.